Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

Mizuho Securities initiated coverage on Enliven Therapeutics Inc ELVN, a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors. The company’s lead product, ELVN-001, is under development for Chronic myelogenous leukemia…#mizuhosecurities #cml #enliventherapeutics #mizuho #tki #novartisags #nvsgleevec #cmltki #elvn
Source: Reuters: Health - Category: Consumer Health News Source Type: news